Drugs / 131I-PSMA-1095
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04085991 | Jul 2020 → Jan 2023 | metastatic prostate carcinoma, prostate adenocarcinoma | Sir Mortimer B. Davis - Jewish General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT03939689 | May 2019 → Sep 2023 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Progenics Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131I-PSMA-1095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04085991 ↗ |
| Known as | I-131-1095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03939689 ↗ |
| Modality | Other / unclassified | “131I-PSMA-1095 radioligand therapy (RLT)” NCT04085991 ↗ |
| Route | Intravenous | “Intravenous injection of 100 mCi of 131I-PSMA-1095” NCT04085991 ↗ |